herein
report
applic
phosphorodiamid
phosphat
prodrug
approach
seri
thirteen
nucleosid
analog
antivir
anticanc
activ
twentyf
symmetr
phosphorodiamid
synthes
bear
esterifi
lalanin
one
case
dalanin
prodrug
moieti
singl
stereoisom
presenc
achir
phosphoru
repres
potenti
advantag
phosphoramid
protid
approach
diastereoisomer
mixtur
routin
obtain
differ
biolog
profil
may
expect
diastereoisom
optim
synthet
pathway
allow
us
identifi
two
gener
method
depend
particular
nucleosid
analog
compound
biolog
evalu
antivir
anticanc
assay
sever
show
improv
activ
compar
parent
nucleosid
case
dda
abacavir
acyclovir
andor
biolog
result
support
metabol
studi
carboxypeptidas
monitor
p
nmr
investig
bioactiv
work
valid
phosphorodiamid
approach
monophosph
prodrug
motif
broad
applic
antivir
anticanc
field
keen
probe
scope
new
diamid
prodrug
motif
across
sever
therapeut
arena
broad
rang
na
context
herein
appli
mcguigan
et
al
nucleosid
analog
na
play
pivot
role
antivir
anticanc
therapi
structur
relat
natur
nucleosid
bear
modif
base
andor
sugar
moieti
case
confer
select
versu
desir
target
na
prodrug
need
convert
activ
speci
usual
consist
form
bioactiv
pathway
often
involv
three
consecut
phosphoryl
step
start
parent
nucleosid
convert
mono
diand
final
triphosph
form
na
abacavir
famciclovir
instanc
requir
also
addit
bioactiv
step
order
display
biolog
activ
first
step
phosphoryl
usual
consid
ratelimit
step
bioactiv
na
except
zidovudin
second
phosphoryl
may
rate
limit
longterm
treatment
na
activ
nucleosid
kinas
involv
first
step
bioactiv
may
decreas
therefor
lead
drug
resist
onset
sever
monophosph
prodrug
strategi
current
investig
overcom
issu
includ
phosphoramid
protid
approach
develop
group
recent
phosphorodiamid
technolog
appli
report
us
new
promis
approach
deliveri
monophosph
insid
cell
sever
stabil
studi
diamid
shown
good
stabil
profil
differ
condit
acid
ph
mild
basic
buffer
ph
human
serum
novel
prodrug
approach
valid
vitro
vivo
compound
alreadi
consider
clinic
studi
similarli
sever
acycl
nucleosid
phosphon
diamid
prodrug
show
better
biolog
profil
compar
parent
compound
approach
two
amino
acid
ester
introduc
monophosph
moieti
order
mask
neg
charg
also
case
phosphoramid
diester
approach
wagner
colleagu
phosphoru
symmetr
diamid
prodrug
achir
thu
avoid
presenc
diastereoisomer
mixtur
case
phosphoramid
protid
deriv
fact
report
two
diastereoisom
may
interact
differ
enzym
involv
bioactiv
pathway
thu
lead
differ
biolog
profil
moreov
diamid
motif
bear
nontox
natur
promoieti
obviat
need
phenyl
naphthyl
moieti
put
bioactiv
pathway
diamid
prodrug
depict
scheme
similar
one
report
protid
first
step
may
mediat
esteras
carboxypeptidasetyp
enzym
respons
cleavag
one
two
ester
mechan
alreadi
describ
support
enzymat
experi
use
p
nmr
second
step
b
involv
intramolecular
attack
carboxyl
anion
phosphoru
elimin
second
amino
acid
format
fivememb
ring
mix
anhydrid
intermedi
spontan
hydrolysi
c
cycl
lead
format
intermedi
bear
two
neg
charg
final
last
step
phosphoramidasetyp
enzym
cleav
pn
bond
form
na
monophosph
diamid
approach
na
either
antivir
anticanc
activ
novel
prodrug
compound
evalu
biolog
activ
na
consid
studi
stavudin
dda
zidovudin
azt
lamivudin
nacetyllamivudin
ribavirin
rbv
acyclovir
acv
abacavir
abc
bicycl
nucleosid
analog
bcna
also
known
acadesin
aica
fig
differ
synthet
condit
necessari
depend
solubl
reactiv
issu
parent
nucleosid
total
twentyf
diamid
synthes
base
previou
work
publish
protid
diamid
select
lalanin
lala
amino
acid
choic
benzyl
prefer
ester
moieti
deriv
methyl
cyclohexyl
ester
consid
one
case
dalanin
dala
use
amino
acid
moieti
first
appli
previous
report
success
methodolog
synthesi
antihcv
cmethylguanosin
dda
azt
procedur
call
method
paper
repres
scheme
strategi
unprotect
nucleosid
dissolv
thf
treat
phosphoru
oxychlorid
equival
presenc
triethylamin
equival
gener
phosphorodichlorid
intermedi
p
nmr
signal
ppm
isol
excess
appropri
amino
acid
ester
ptoluen
sulfon
ptsa
salt
usual
equival
triethylamin
equival
ad
lead
stir
room
temperatur
h
desir
phosphorodiamid
p
nmr
signal
p
ppm
interestingli
case
function
group
react
yield
tetradiamid
deriv
deriv
scheme
howev
appli
na
report
work
method
success
probabl
due
lack
solubl
organ
solvent
use
base
find
modif
synthet
approach
report
yoshikawa
et
al
synthesi
monophosph
speci
use
method
previous
report
synthesi
phosphorodiamid
second
strategi
name
method
b
use
synthesi
diamid
nacetyl
rbv
acv
abc
aica
scheme
nmr
p
addit
excess
appropri
amino
acid
ester
salt
presenc
dipea
tea
yield
desir
phosphorodiamid
arylphosphoramid
protid
technolog
monophosph
prodrug
approach
proven
power
tool
term
enhanc
biolog
activ
bypass
certain
mechan
resist
well
extend
biolog
profil
sever
na
moreov
increas
lipophil
prodrug
may
also
lead
better
deliveri
insid
cell
passiv
diffus
thu
favor
greater
uptak
drug
instanc
report
applic
protid
approach
greatli
enhanc
antivir
activ
antihepat
c
viru
hcv
agent
purin
overcam
mechan
resist
extend
biolog
profil
bvdu
acv
antiherpet
anticanc
antihuman
immunodefici
viru
hiv
agent
respect
similar
context
phosphorodiamid
report
test
versu
differ
cancer
cell
line
well
versu
rang
virus
aim
investig
full
potenti
phosphat
prodrug
moieti
probe
deliveri
monophosph
insid
cell
thu
bypass
first
step
phosphoryl
thymidin
kinasedefici
tk
mutant
cancer
cell
herp
viru
strain
also
use
tabl
report
anticanc
activ
dda
abc
aica
respect
phosphorodiamid
versu
mous
lymphocyt
leukemia
cell
human
tlymphocyt
cell
cem
human
cervic
carcinoma
cell
hela
tk
mutant
strain
also
includ
cemtk
helatk
colorect
adenocarcinoma
cell
human
colon
carcinoma
cell
expect
show
antiprolif
activ
versu
human
cancer
cell
line
consid
studi
case
murin
show
cytostat
activ
found
ineffect
versu
confirm
expect
depend
tk
phosphoryl
eventu
biolog
activ
contrari
phosphorodiamid
show
antiprolif
activ
versu
cancer
cell
line
rang
cem
hela
poorli
effect
versu
cell
importantli
compound
show
retent
activ
tk
strain
rang
versu
vs
cemtk
vs
helatk
strain
result
strongli
suggest
success
deliveri
monophosph
insid
cell
thu
head
independ
tk
activ
altern
hypothesi
could
assum
similar
antiprolif
activ
observ
prodrug
tk
cell
versu
wildtyp
cell
could
due
direct
effect
prodrug
prodrug
moieti
releas
benzyl
part
molecul
howev
highli
unlik
case
prodrug
would
expect
display
similar
toxic
differ
prodrug
molecul
ie
case
similar
trend
observ
phosphorodiamid
fact
parent
nucleosid
found
inact
versu
cancer
cell
line
compound
show
certain
antiprolif
activ
rang
test
tumor
cell
line
includ
tk
mutant
strain
expect
phosphorotetramid
nphosphorodiamid
show
activ
particular
interest
case
dda
abc
prodrug
parent
nucleosid
show
potent
antiprolif
activ
vs
cem
hela
dda
vs
cem
vs
hela
abc
prodrug
show
great
enhanc
activ
show
ic
valu
dda
deriv
rang
abc
phosphat
prodrug
neither
aica
prodrug
show
activ
may
indic
poor
convers
prodrug
free
monophosph
discuss
one
advantag
monophosph
prodrug
approach
bypass
first
phosphoryl
step
mediat
human
andor
viral
kinas
enzym
monophosph
prodrug
report
test
antivir
activ
versu
differ
virus
dda
azt
acv
abc
respect
phosphorodiamid
test
cem
cell
tabl
compound
show
boost
activ
fold
vs
fold
vs
compar
parent
deriv
case
dda
markedli
greater
boost
activ
vs
vs
observ
prodrug
azt
deriv
equipot
parent
deriv
significantli
less
effect
except
nphosphorodiamid
surprisingli
two
fold
less
activ
case
abc
compound
show
increas
potenc
fold
compar
parent
nucleosid
case
acv
great
improv
biolog
profil
observ
fact
acv
abl
inhibit
ec
phosphorodiamid
show
inhibitori
activ
low
micromolar
rang
thu
lead
fold
boost
activ
posit
result
obtain
may
due
combin
success
deliveri
monophosph
form
parent
nucleosid
insid
cell
well
enhanc
cellular
uptak
due
increas
lipophil
howev
posit
featur
monophosph
prodrug
also
led
case
slightli
increas
cytotox
compar
parent
compound
case
phosphoramid
poor
antihiv
activ
may
due
poor
metabol
bioactiv
phosphat
prodrug
moieti
subsequ
poor
releas
free
monophosph
form
fact
uptak
metabol
activ
prodrug
multistep
process
current
clear
enzym
contribut
eventu
activ
prodrug
differ
type
enzym
involv
drug
convers
pathway
yet
clarifi
also
differenti
specif
relat
natur
nucleosid
prodrug
part
activ
level
differ
cell
system
exactli
known
without
doubt
subtl
differ
play
role
eventu
biolog
activ
properti
compound
phosphorodiamid
approach
prodrug
appli
show
outstand
result
versu
hcv
vitro
vivo
driven
encourag
result
seri
diamid
compound
interest
versu
hcv
prepar
includ
rbv
acv
tabl
unfortun
major
compound
show
poor
biolog
profil
except
compound
deriv
compound
fact
compound
show
inhibitori
activ
hcv
submicromolar
rang
show
great
boost
activ
compar
parent
guanosin
nucleosid
ec
notabl
lalanin
deriv
gave
fold
improv
activ
compar
bear
nonnatur
amino
acid
dalanin
base
previou
studi
find
may
result
lower
convers
dalanin
base
phosphat
prodrug
monophosph
consequ
lower
affin
enzym
involv
bioactiv
pathway
activ
aica
acv
diamid
evalu
human
herp
simplex
viru
hsv
type
felin
herp
viru
report
tabl
aica
respect
phosphorodiamid
prodrug
devoid
activ
human
felin
herp
virus
ec
tabl
case
acv
parent
show
submicromolar
activ
versu
prodrug
show
loss
fold
antivir
activ
howev
test
tk
acv
fold
less
effect
ec
diamid
retain
activ
found
equipot
parent
compound
thu
indic
tk
independ
inde
sinc
acv
obligatorili
need
convert
activ
monophosph
deriv
tk
markedli
lower
antivir
activ
tk
strain
wherea
prodrug
ascertain
prodrug
direct
activ
purifi
herpet
dna
polymeras
exclud
possibl
prodrug
might
activ
replic
phosphorodiamid
prodrug
also
examin
inhibitori
activ
varieti
virus
includ
vaccinia
viru
vesicular
stomat
viru
influenza
viru
b
felin
corona
viru
fipv
viru
sindbi
viru
coxsacki
viru
punta
toro
viru
respiratori
syncyti
viru
coxsacki
viru
none
show
inhibitori
activ
cytotox
depict
scheme
put
bioactiv
pathway
phosphorodiamid
phosphat
moieti
involv
two
enzymat
step
mediat
esteras
carboxypeptidas
type
enzym
first
step
phosphoramidas
type
enzym
last
step
report
investig
first
step
bioactiv
pathway
protid
diamid
incub
desir
compound
carboypeptidas
enzym
aceton
trizma
buffer
ph
follow
progress
process
p
nmr
prodrug
test
prove
chemic
robust
trizma
buffer
ph
environ
absenc
carboxypeptidas
fig
report
first
enzymat
cleavag
acv
prodrug
activ
compound
aica
prodrug
inact
compound
respect
compound
p
show
fast
metabol
first
intermedi
lack
one
ester
moieti
cleavag
one
ester
support
presenc
two
peak
p
nmr
p
thu
indic
chiral
phosphoru
min
addit
enzym
new
peak
p
appear
correspond
metabolit
lack
one
amino
acid
one
ester
agreement
previous
publish
result
notabl
compound
fulli
convert
h
metabolit
indic
first
step
bioactiv
pathway
proce
well
acv
deriv
contrari
poor
metabol
observ
compound
fact
condit
use
compound
partial
convers
desir
metabolit
p
observ
h
start
materi
p
still
predomin
speci
two
exampl
report
correl
biolog
activ
found
bioactiv
effici
thu
support
need
ester
cleavag
bioactiv
pathway
class
compound
howev
intracellular
activ
prodrug
still
need
confirm
conclus
report
synthesi
biolog
evalu
twentyf
phosphorodiamid
prodrug
known
na
key
advantag
nucleosid
monophosph
prodrug
approach
overcom
chiral
phosphoru
center
present
monophosph
prodrug
approach
thu
allow
format
singl
stereoisom
instead
diastereoisomer
mixtur
broad
anticanc
antivir
evalu
perform
mani
compound
show
good
improv
andor
extens
biolog
profil
great
improv
activ
observ
case
dda
abc
acv
phosphorodiamid
prodrug
show
good
inhibitori
activ
versu
differ
cancer
cell
line
contrari
aica
deriv
show
neither
anticanc
antivir
activ
metabol
assay
use
carboxypeptidas
perform
support
import
bioactiv
compound
exert
activ
fact
compound
slowli
activ
assay
either
low
activ
observ
test
wherea
rapid
bioactiv
result
improv
biolog
profil
phosphorodiamid
approach
report
show
consider
promis
across
biolog
spectrum
na
activ
believ
significantli
augment
field
nucleotid
prodrug
use
drug
discoveri
anhydr
solvent
purchas
sigmaaldrich
amino
acid
ester
novabiochem
reagent
commerci
avail
use
without
purif
thin
layer
chromatographi
tlc
precoat
aluminum
back
plate
f
mm
thick
merck
visual
short
long
wave
uv
light
nm
flash
column
chromatographi
carri
use
silica
gel
suppli
fisher
mm
analyt
high
perform
liquid
chromatographi
hplc
analysi
perform
use
either
thermoscientif
varian
prostar
system
h
nmr
mhz
c
nmr
mhz
p
nmr
mhz
f
nmr
mhz
spectra
record
bruker
avanc
mhz
spectromet
chemic
shift
quot
part
per
million
ppm
rel
intern
meod
h
nmr
c
nmr
cdcl
h
nmr
c
nmr
extern
h
po
p
nmr
coupl
constant
j
given
hertz
follow
abbrevi
use
assign
nmr
signal
singlet
doublet
triplet
q
quartet
qn
quintet
multiplet
bs
broad
singlet
dd
doublet
doublet
dt
doublet
triplet
low
resolut
mass
spectrometri
perform
bruker
dalton
microtoflc
system
servic
school
chemistri
cardiff
univers
solutionsuspens
desir
nucleosid
moleq
anhydr
thf
anhydr
et
n
moleq
ad
argon
atmospher
stir
room
temperatur
min
pocl
moleq
ad
dropwis
reaction
mixtur
stir
min
allow
warm
room
temperatur
anhydr
ch
cl
appropri
amino
acid
ester
salt
moleq
ad
follow
dropwis
addit
anhydr
et
n
moleq
reaction
mixtur
stir
room
temperatur
period
h
ad
aqueou
phase
extract
ch
cl
organ
phase
wash
brine
dri
anhydr
na
mgso
fillter
evapor
dryness
residu
purifi
silica
gel
column
chromatographi
use
differ
eluent
system
solut
desir
nucleosid
moleq
trimethylphosph
triethylphosph
pocl
moleq
ad
dropwis
argon
atmospher
reaction
mixtur
stir
h
h
anhydr
ch
cl
appropri
amino
acid
ester
salt
moleq
ad
follow
dropwis
addit
anhydr
et
n
moleq
anhydr
dipea
moleq
reaction
mixtur
stir
min
room
temperatur
h
period
h
ad
aqueou
phase
extract
ch
cl
organ
phase
wash
brine
dri
anhydr
na
mgso
filter
evapor
dryness
residu
purifi
silica
gel
column
chromatographi
use
differ
eluent
system
dmf
ml
ad
g
mmol
mixtur
stir
nitrogen
atmospher
min
room
temperatur
acet
anhydrid
ml
mmol
ad
dropwis
mixtur
stir
room
temperatur
overnight
solvent
remov
reduc
pressur
residu
azeotrop
toluen
crude
solid
wash
diethyl
ether
ml
give
desir
compound
white
solid
g
accord
standard
procedur
use
g
mmol
anhydr
thf
ml
anhydr
et
n
ml
mmol
pocl
ml
mmol
anhydr
ch
cl
ml
tosyl
salt
g
mmol
ad
follow
dropwis
addit
anhydr
et
n
ml
mmol
reaction
mixtur
stir
room
temperatur
overnight
workup
crude
residu
purifi
silica
gel
column
chromatographi
elut
chcl
meoh
give
product
white
solid
g
accord
standard
procedur
use
g
mmol
anhydr
thf
ml
anhydr
et
n
ml
mmol
pocl
ml
mmol
anhydr
ch
cl
ml
tosyl
salt
benzoxylalanin
g
mmol
ad
follow
dropwis
addit
anhydr
et
n
ml
mmol
reaction
mixtur
stir
room
temperatur
overnight
workup
crude
residu
purifi
silica
gel
column
chromatographi
elut
gradient
meoh
ch
cl
yield
product
white
solid
g
prepar
accord
standard
procedur
use
g
mmol
anhydr
thf
ml
anhydr
et
n
ml
mmol
pocl
ml
mmol
anhydr
ch
cl
ml
tosyl
salt
cyclohexoxylalanin
g
mmol
ad
follow
dropwis
addit
anhydr
et
n
ml
mmol
reaction
mixtur
stir
room
temperatur
h
workup
crude
residu
purifi
silica
gel
column
chromatographi
elut
gradient
meoh
ch
cl
afford
product
solid
g
anhydr
ch
cl
ml
tosyl
salt
g
mmol
ad
follow
dropwis
addit
anhydr
et
n
ml
mmol
reaction
mixtur
stir
room
temperatur
h
workup
crude
residu
purifi
silica
gel
column
chromatographi
elut
gradient
meoh
ch
cl
give
product
white
solid
g
accord
standard
procedur
use
g
mmol
anhydr
thf
ml
anhydr
et
n
ml
mmol
pocl
ml
mmol
anhydr
ch
cl
ml
tosyl
salt
g
mmol
ad
follow
dropwis
addit
anhydr
et
n
ml
mmol
reaction
mixtur
stir
room
temperatur
h
workup
crude
residu
purifi
silica
gel
column
chromatographi
elut
gradient
meoh
chcl
give
product
white
solid
g
prepar
accord
standard
procedur
b
use
g
mmol
trimethylphosph
ml
pocl
ml
mmol
reaction
mixtur
stir
h
anhydr
ch
cl
ml
tosyl
salt
benzoxylalanin
g
mmol
ad
follow
dropwis
addit
anhydr
dipea
ml
mmol
reaction
mixtur
stir
room
temperatur
h
workup
crude
residu
purifi
silica
gel
column
chromatographi
elut
gradient
meoh
ch
cl
give
product
white
solid
g
prepar
accord
standard
procedur
b
use
reaction
mixtur
stir
h
anhydr
ch
cl
ml
tosyl
salt
benzoxylalanin
g
mmol
ad
follow
dropwis
addit
anhydr
et
n
ml
mmol
reaction
mixtur
stir
room
temperatur
h
workup
crude
residu
purifi
silica
gel
column
chromatographi
elut
gradient
meoh
chcl
give
product
white
solid
g
accord
standard
procedur
b
use
g
mmol
trimethylphosph
ml
pocl
ml
mmol
reaction
mixtur
stir
h
anhydr
ch
cl
ml
tosyl
salt
g
mmol
ad
follow
dropwis
addit
anhydr
et
n
ml
mmol
reaction
mixtur
stir
room
temperatur
h
workup
crude
residu
purifi
silica
gel
column
chromatographi
elut
gradient
meoh
chcl
give
product
white
solid
g
prepar
accord
standard
procedur
b
use
g
mmol
trimethylphosph
ml
pocl
ml
mmol
reaction
mixtur
stir
h
anhydr
ch
cl
ml
suspens
tosyl
salt
benzoxylalanin
g
mmol
anhydr
ch
cl
ml
ad
follow
dropwis
addit
anhydr
dipea
ml
mmol
reaction
mixtur
stir
room
temperatur
h
workup
crude
residu
purifi
silica
gel
column
chromatographi
elut
gradient
meoh
ch
cl
give
product
white
solid
g
synthesi
phoshat
prepar
accord
standard
procedur
b
use
g
mmol
trimethylphosph
ml
pocl
ml
mmol
reaction
mixtur
stir
h
anhydr
ch
cl
ml
suspens
tosyl
salt
g
mmol
anhydr
ch
cl
ml
ad
follow
dropwis
addit
anhydr
dipea
ml
mmol
reaction
mixtur
stir
room
temperatur
h
workup
crude
residu
purifi
silica
gel
column
chromatographi
elut
gradient
meoh
ch
cl
give
product
white
solid
g
prepar
accord
standard
procedur
b
use
g
mmol
trimethylphosph
ml
pocl
ml
mmol
reaction
mixtur
stir
h
anhydr
ch
cl
ml
suspens
tosyl
salt
benzoxylalanin
g
mmol
anhydr
ch
cl
ml
ad
follow
dropwis
addit
anhydr
dipea
ml
mmol
reaction
mixtur
stir
room
temperatur
h
workup
crude
residu
purifi
silica
gel
column
chromatographi
elut
gradient
e
meoh
ch
cl
give
white
solid
dissolv
ch
cl
wash
n
hcl
ml
brine
ml
nahco
ml
brine
ml
dri
mgso
filter
concentr
give
product
white
solid
g
mmol
trimethylphosph
ml
pocl
ml
mmol
reaction
mixtur
stir
h
anhydr
ch
cl
ml
suspens
tosyl
salt
g
mmol
anhydr
ch
cl
ml
ad
follow
dropwis
addit
anhydr
dipea
ml
mmol
reaction
mixtur
stir
room
temperatur
h
workup
crude
residu
purifi
silica
gel
column
chromatographi
elut
gradient
meoh
ch
cl
product
dissolv
ch
cl
wash
n
hcl
ml
brine
ml
nahco
ml
brine
ml
dri
mgso
filter
concentr
give
product
white
solid
g
prepar
accord
standard
procedur
b
use
tumor
cell
seed
microtit
plate
expos
differ
concentr
test
compound
day
day
cem
cemtk
hela
hela
tk
cell
number
determin
use
particl
counter
coulter
anali
ghent
belgium
ic
repres
compound
concentr
requir
inhibit
tumor
cell
prolifer
transfer
micropl
well
mix
ml
medium
contain
test
compound
appropri
dilut
incub
day
product
measur
cell
cultur
supernat
result
given
mean
standard
error
mean
concentr
requir
suppress
viral
replic
median
effect
concentr
valu
calcul
fit
data
point
sigmoid
doseerespons
curv
prism
softwar
version
graphpad
viabil
assay
viabil
assay
perform
cell
cultur
nucleocount
autom
cell
count
system
chemometec
total
number
cell
number
dead
cell
cultur
untreat
treat
acv
protid
enumer
use
propidium
iodidebas
assay
accord
manufactur
protocol
data
collect
analyz
use
nucleoview
softwar
chemometec
denmark
compound
mg
mg
dissolv
aceton
ml
trizma
buffer
ph
ml
p
nmr
record
blank
solut
carboxypeptidas
mg
trizma
buffer
ml
ad
p
nmr
experi
perform
record
experi
everi
min
h
room
temperatur
put
bioactiv
pathway
diamid
prodrug
enzymemedi
ester
hydrolysi
b
spontan
intracellular
displac
c
spontan
hydrolysi
enzymemedi
pn
bond
cleavag
mcguigan
et
al
page
tabl
inhibitori
effect
prolifer
tumor
cell
line
cell
cultur
ic
inhibitori
concentr
